Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Nivolumab 3 Cisplatin 3 atezolizumab 2 Irinotecan 2 Ipilimumab 2 Etoposide 2 Carboplatin 2 tivozanib 1 repotrectinib 1 niraparib 1 gallium Ga 68 dotatate 1 dostarlimab 1 cabozantinib 1 budigalimab 1 belinostat 1 Topotecan 1 Temozolomide 1 Specimen Handling 1 Radiosurgery 1 Radionuclide Imaging 1 Positron-Emission Tomography 1 Positron Emission Tomography Computed Tomography 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Immunoglobulin G 1 IFL protocol 1 Fluorouracil 1 Disulfides 1 DLL3 protein, human 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Neuroendocrine × DLL3 protein, human × 90 days × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡